21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
21:34 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Axovant discontinuing intepirdine for AD after Phase III miss

Axovant Sciences Ltd. (NYSE:AXON) said it will discontinue development of intepirdine (RVT-101) to treat mild to moderate Alzheimer’s disease after the product missed the co-primary endpoints in the Phase III MINDSET trial in the indication....
22:40 , Sep 26, 2017 |  BC Extra  |  Clinical News

Axovant plummets after intepirdine AD miss

Axovant Sciences Ltd. (NYSE:AXON) fell $17.92 (74%) to $6.33 on Tuesday after discontinuing development of intepirdine (RVT-101) to treat mild to moderate Alzheimer’s disease after the product missed the co-primary endpoints in the Phase III...
21:47 , Jul 21, 2017 |  BioCentury  |  Product Development

Surrogate start

Phase II results for Probiodrug AG’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in Phase...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
18:49 , May 12, 2017 |  BC Week In Review  |  Company News

Adamas, HCR in $100M royalty deal

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) will receive a loan worth up to $100 million via a royalty note deal with HealthCare Royalty Partners (Stamford, Conn.). The company is to receive $35 million up front and $65...
23:13 , May 11, 2017 |  BC Extra  |  Financial News

Adamas, HCR in $100M royalty deal

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) is to receive a loan worth up to $100 million via a royalty note deal with HealthCare Royalty Partners. The company is to receive $35 million up front and $65 million...
21:20 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Idalopirdine: Ph III STARBRIGHT data

Lundbeck said data from the double-blind, placebo-controlled, international Phase III STARBRIGHT trial in about 734 patients with mild to moderate AD who were on stable treatment with an acetylcholinesterase (AChE) inhibitor showed that oral idalopirdine...